Should You Buy, Sell, or Hold BHEL After Q1 FY27 Results? Here’s What Brokerages Say

BHEL has posted its first-quarter results for FY27, sparking a rare divergence of opinion among brokerage houses. Nuvama has become the lone bull, raising its target price to ₹530, based on a thesis that the company is finally on the path to margin recovery. However, a majority of major global and domestic firms, including Kotak, JPMorgan, Macquarie, and CLSA, have maintained their 'sell' ratings. These firms argue that the stock's recent price rally has significantly outpaced the underlying quality of its earnings.

For investors, this split presents a classic dilemma. The bull case rests on the hope that BHEL's operational efficiency will improve, while the bearish view suggests the market is currently pricing in optimism that may not be fully supported by fundamentals. The stock's performance will likely hinge on whether the company can sustain any operational gains or if the price action is purely speculative.

Investors should closely monitor the company's order inflows and debt levels in the coming quarters. The key will be to see if the operational improvements are real and durable or if the current rally is simply a short-term phenomenon. Watching for any updates on the company's debt reduction strategy will also be crucial for assessing its long-term financial health.